AB Science
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease
Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease
Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m
The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
The neurodegenerative disease affects approximately 30,000 people in the US
Researchers develop new approach to target cells affected by motor neurone disease
The technique could lead to safer and more effective gene therapies for the neurodegenerative disease
LifeArc and King’s College London partner to accelerate treatment for motor neurone disease
The rare neurodegenerative disease affects one in every 300 people in the UK
NIHR partners with Motor Neurone Disease Association for MND research
The partnership will speed up the discovery of treatments and insights for MND
Innovate UK awards Sano Genetics £330,000 grant for ALS study
The project will chart the psychological impacts of having a genetic predisposition to ALS
Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS
Mutations in the SOD1 gene are responsible for approximately 2% of all cases
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The neurodegenerative disease affects approximately 27,000 people in the US
UK Government commit £50m to motor neurone disease research
The pledged funding is being placed into the hands of researchers ‘as quickly as possible’
Verge Genomics begins human trials with AI-sourced ALS drug
VRG50635 was discovered by the company’s all-in-human, AI-powered platform